Allogene Therapeutics (ALLO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 03/07/23
After Plunging -23.01% in 4 Weeks, Here's Why the Trend Might Reverse for Allogene Therapeutics (ALLO)Zacks Investment Research • 03/06/23
Goldman Sachs Has 5 Stellar Stocks to Buy Under $10 With Up to 735% Upside Potential24/7 Wall Street • 03/04/23
Allogene: ALLO-715 Phase 1 Results And ALLO-213 Preclinical Data Is PromisingSeeking Alpha • 03/03/23
Allogene Therapeutics Announces Participation in Two Upcoming Investor ConferencesGlobeNewsWire • 03/02/23
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular TherapyGlobeNewsWire • 03/01/23
Allogene Therapeutics (ALLO) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 02/28/23
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 02/28/23
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023GlobeNewsWire • 02/21/23
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/15/23
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform TechnologyGlobeNewsWire • 02/01/23
Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law FirmNewsfile Corp • 01/26/23
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung CancerGlobeNewsWire • 01/25/23
Allogene Therapeutics (ALLO) Soars 15.7%: Is Further Upside Left in the Stock?Zacks Investment Research • 01/25/23
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple MyelomaGlobeNewsWire • 01/24/23
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/23
Down -41.38% in 4 Weeks, Here's Why Allogene Therapeutics (ALLO) Looks Ripe for a TurnaroundZacks Investment Research • 12/29/22
Wall Street Analysts Think Allogene Therapeutics (ALLO) Could Surge 159%: Read This Before Placing a BetZacks Investment Research • 12/08/22